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1. Introduction 
Common feature found in several natural ionophores is the 
presence of a lipophilic, usually rigid, backbone connected to a 
hydrophilic subunit. Two cases in point are constituted by 
amphotericin B (AmB) and squalamine (Figure 1). The first one
1
 
is a macrocyclic compound in which the hydrophobic portion is a 
conjugate polyene and the hydrophilic one is a polyol. 
Squalamine, on the contrary, is a sterol-spermidine conjugate that 
has been isolated from tissues of the dogfish shark, Squalus 
acanthias, in 1993 (Figure 1).
2
 Both compounds show 
remarkable biological activity, in particular as antifungal (AmB)
3
 
and antibacterial (squalamine)
4
 agents, which is thought to be 
related to their ability to perturb the cellular membrane 
permeability.
5,6,7
 While the macrocyclic nature of AmB ensures a 
stable facially amphipathic structure that is responsible of its 
activity, the active conformation of squalamine is still matter of 
controversy. Following the analysis proposed by Regen,
8,9
 its key 
functional elements are i) the long and rigid hydrophobic steroid 
nucleus; ii) the flexible hydrophilic spermidine chain terminating 
with a positively charged amino group; iii) the anionic polar head 
group. The arrangement of these three units favors the formation 
of a pseudomacrocyclic structure, like the one shown in Figure 1, 
possibly stabilized by a salt bridge between the terminal primary 
ammonium group and the sulphate moiety, which is located at 
the opposite end of the molecule. In this conformation the 
pseudomacrocycle is characterized by a facially amphipathic 
structure analogous to that of AmB and it may insert in the 
membrane altering its permeability. Mimics of such molecules 
(particularly squalamine) have been reported
10
 with interesting 
ionophoric activity and in some cases powerful antibiotic activity 
similar to that of the natural compound.
11
 In all cases, however, 
the hydrophobic element so far exploited has been a steroid 
backbone. 
Following our interest in synthetic ionophores
12
 and in 
particular in the use of peptide foldamers as structural/functional 
design elements,
13
 we reasoned that the rigid hydrophobic 
backbone may be substituted by a lipophilic peptide in its helical 
conformation with advantages in term of synthetic accessibility, 
control of the size and insertion of functional group along the 
peptide backbone. We focused on an acyclic compound (as 
squalamine) and designed compounds 1a,b (Figure 1). In these 
molecules the hydrophobic portion is constituted by a homo-
octapeptide made by the ,-disubstituted amino acid Aib (-
amino-isobutyric acid). The peptide was then modified on the N-
terminus with a phosphate moiety linked through a phenyl spacer 
as an anionic head group and on the C-terminus with a spermine 
chain (1a) or with a short polyether chain ending with an ammine 
group (1b). The 8-mer Aib sequence was chosen because it is 
well known to assume a stable 310-helical conformation
14
 in 
apolar solvents,
15
 that is maintained in membrane–like 
environments.
16
 Furthermore, in view of the ionophoric ability of 
peptaibols,
17
 short helical peptides rich in Aib amino acids, this 
structural feature could add an extra activity to the system. Due 
to the gem--dimethyl substituents, the helix is hydrophobic thus 
representing, in our design, a pseudo-rigid linear hydrophobic 
element that may well insert in the phospholipid membrane. In 
this conformation the length of the hydrophobic portion of 
compounds 1, comprising the peptide and the N-terminal phenyl 
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substituent, is about 19 Å, which is sufficient to span the 
hydrocarbon region of a phospholipid monolayer (i.e. one leaflet 
of a membrane). Therefore, we hypothesized that 1 could bind to 
the membrane by anchoring the phosphate head group at the 
surface and inserting the hydrophobic peptide parallel to the fatty 
acid hydrocarbon chains. The hydrophilic spermine or polyether 
chain, which is attached to the rigid peptide at the opposite side 
of the phosphate head group, might then extend along the peptide 
toward the membrane surface forming an amphipathic pseudo-
macrocyclic structure or might extend in the opposite direction 
reaching the membrane surface on the other side. This is possible 
since 1a,b are acyclic molecules, at variance with AmB and in 
analogy to squalamine. At any rate, in both cases the membrane 
should be destabilized resulting in increased ion permeability. In 
this work we report on the synthesis and characterization of the 
new squalamine mimics, on the investigation of their ion 
transport properties across phospholipid membranes as well as in 
vitro data on their antimicrobic activity. 
 
Figure 1. Chemical structures of amphotericin B, squalamine, and of the 
synthetic ionophores (1a and 1b) investigated in this work. 
2. Result and Discussion 
2.1 Chemistry 
Conjugates 1 were prepared starting from the Z-(Aib)8-OtBu 
peptide (Scheme 1, tBu = tert-butyl, Z = benzyloxycarbonyl) that 
was synthesized by conventional solution peptide chemistry 
following the procedure reported by Toniolo et al.
18
 Deprotection 
of the C-terminus with trifluoroacetic acid (TFA) and coupling 
with tri-Boc-spermine in presence of (benzotriazol-1-
yloxy)tris(dimethylamino)phosphonium hexafluorophosphate 
(Py-BOP) at room temperature afforded the intermediate 3a. This 
was deprotected at the N-terminus by catalytic hydrogenation and 
coupled with 4-[[bis(phenylmethoxy)phosphinyl]oxy]benzoic 
acid (10) using N-(3-Dimethylaminopropyl)-N′-
ethylcarbodiimide (EDC) and 1-hydroxybenzotriazole (HOBt) as 
condensing agents. Full removal of the Boc from the amino 
groups and of the benzyl esters from the phosphate moiety with 
TFA afforded 1a as a trifluoroacetate salt. 
 
Scheme 1: a) TFA, CH2Cl2, r.t., 4 h, quant.; b) Py-BOP, N,N-
diisopropylethylamine (DIEA), CH2Cl2, r.t., 24 h, 58%; c) (CH3CO)2O, 
reflux, 3 h, 97%; d) Triethylamine (TEA), CH3CN, r.t, 24 h, 77%; e) (Boc)2O, 
CH2Cl2, r.t., 3 h, 45%; f) H2, Pd/C, CH3OH, r.t., 24h, quant.; g) EDC, HOBt, 
TEA, CH2Cl2, r.t., 24 h; h) TFA, CH2Cl2, r.t., 24h, quant. 
 
Intermediate 3b was obtained by a slightly different procedure 
in which the Z-(Aib)8-OH was first transformed into the 
corresponding 5(4H)-oxazolone by reaction with acetic 
anhydride. Reaction of the oxazolone with pentaoxaheptadecane-
1,17-diamine followed by Boc-protection of the free terminal 
primary amine afforded intermediate 3b. This was then subjected 
to the same steps as 3a giving 1b as a trifluoroacetate salt, after 
final treatment with TFA. Compounds 1a,b have been fully 
characterized by 
1
H and 
13
C NMR and MS analysis 
2.2 Ion transport across lipid membranes 
The ability of conjugates 1 to permeabilize a phospholipid 
model membrane was evaluated with two different assays using 
large unilamellar vesicles (100 nm diameter) with a 95:5 egg 
phosphatidylcholine (PC) and egg phosphatidylglycerol (PG) 
lipid composition. In the first assay the transport of Na
+
 from 
outside to inside the membrane was evaluated using 
23
Na
+
 NMR 
and a shift reagent (DyCl3–tripolyphosphate) to differentiate the 
population of Na
+
 inside the liposome water pool from bulk Na
+
. 
In the experiment, a gradient of Na
+
 is built up by addition of 
NaCl after vesicle formation (NaCl 100 mM outside, 0 mM 
inside). Since the shift reagent is confined in the external bulk 
aqueous phase, the Na
+
 entering the vesicular compartment 
appears as a separate (unshifted) resonance and integration of 
internal Na
+
 signal, as a function of time, yields the kinetics 
profiles shown in Figure 2a. Conjugate 1b is highly effective in 
promoting the transport of Na
+
 across the phospholipid 
membrane and its activity is even higher than that recorded for 
AmB taken as a positive reference compound. On the contrary, 
1a is almost inactive and after more than 13 h the amount of Na
+
 
entering the internal vesicular compartment is only slightly 
higher than in the absence of any additive. The inability of 
spermine functionalized ionophores to promote cation transport 
has been previously observed,
19 
and it was attributed to the 
inability of the positively charged polyamine chain to stabilize 
the cation during the crossing of the membrane. Fitting of the 
kinetics traces recorded for different concentrations of 1b 
afforded the first-order rate constants (kNa
+
, min
-1
) for the 
transport process that are reported in Figure 2b. The profile 
shows a linear increase of activity with the concentration of 1b, 
indicating that the species responsible for the transport process is 
monomeric, at least in the concentration range explored. 
  
Figure 2. a) Kinetics profiles for the entry of Na+ into 95:5 egg PC/PG 
vesicles containing 1a, 1b, AmB (1 %) and without additives (control) at 25 
°C. b) Dependence of the observed rate constant for the transport process 
(kNa
+, min-1) vs. concentration of 1b, (see Supplementary Material for the 
original kinetics traces). The concentration of ionophores is given in percent 
with respect to the total concentration of lipids (10 mM). 
 
In a second assay we evaluated the ability of the ionophores to 
dissipate a pH gradient across the membrane exploiting the 
response of the intravesicular pH-sensitive fluorophore 8-
hydroxypyrene-1,3,6-trisulfonic acid (HPTS).
20
 In this 
experiment a 0.6 units pH gradient is established, by external 
addition of NaOH, across the membrane of vesicles prepared in 
HEPES buffer at pH 7.0 containing 100 mM NaCl (HEPES = 4-
(2-hydroxyethyl)piperazine-1-ethanesulfonic acid). The increase 
of the HPTS fluorescence emission in response to the applied 
transmembrane pH-gradient indicates basification of the inner 
water pool that may derive either from H
+
 efflux or OH
-
 influx.  
  
Figure 3. a) Normalized fluorescence change in HPTS emission as a 
function of time after base pulse to 95:5 PC/PG vesicles containing 1a, 1b, 
AmB (1 %) and without additives (control) at 25 °C. b) Dependence of the 
observed rate constant for the transport process (kH
+, s-1) vs concentration of 
compounds 1 (see Supplementary Material for the original kinetics traces). 
The curves correspond to the fitting of the data with the Regen’s equation 
reported in the graph. The concentration of ionophores is given in percent 
with respect to the total concentration of lipids (0.17 mM). 
 
Figure 3a shows the kinetics profiles obtained in the presence 
of conjugates 1 and AmB in the HPTS assay. The two conjugates 
are considerably effective in promoting the pH gradient collapse 
showing higher activity with respect to AmB. In this assay 1a 
and 1b show a very similar activity as well as a similar 
dependence of the transport rate from the concentration of 
ionophore (Figure 3b). However, in this case the profiles show an 
upward curvature and interpolation of the experimental points 
with the equation proposed by Regen
9
 gives n = 2.5 and 2.1 for 
1a and 1b, respectively, suggesting that the species responsible 
for the ionophoric effect is an aggregate formed by 
approximately two peptide monomers. 
Taken together, these data show that the two peptide 
conjugates have a high ionophoric activity in model membranes. 
As reported above, it is reasonable to assume that compounds 1 
insert in the membrane with the phosphate head group anchored 
to the surface while the hydrophobic peptide aligns with the fatty 
acid hydrocarbon chains. Here the hydrophilic chain perturbs the 
membrane creating defects that allow the transit of the ions. The 
different behaviour observed in the Na
+
 transport and in the pH 
discharge experiment is probably related to the different 
requirements of the two transport processes. Indeed, while Na
+
 
has to be stabilized by specific interactions with the ionophore 
during the crossing of the membrane, the pH discharge may 
occur by a hydrogen-bonded chain mechanism in which the 
proton hops from one molecule of water to the next along a water 
molecules transmembrane chain (Grotthuss’ mechanism).
21
 In 
this case, a direct interaction with the ion is not required and the 
ionophore accelerates the transport process by stabilizing the 
transmembrane water row. It is tempting to suggest that the 
polyether chain shuttles Na
+
 from the surface of the external 
leaflet of the liposomal membrane to the internal water pool. This 
would explain the requirement of monomeric 1b molecule, while 
in the case of the pH discharge the stabilization of the water 
channel requires the alignment of two ionophore molecules to 
fully span the membrane. Moreover, the inability to transport Na
+
 
associated with potent pH discharge activity suggests that 1a 
forms anion selective pores in which the transport of H
+
 (or OH
-
) 
is counterbalanced by the transport of chloride in analogy with 
the anion selective transport mechanism described for squalamine 
mimics bearing polyamine chains.
19a,22
 In any case, control 
experiments with the relatively large calcein dye indicate that, 
whatever the mechanism, the membrane defects formed by 
conjugates 1 are not large enough to allow the transport of 
calcein and that the ionophores are not able to cause lysis of the 
liposomes (see Supplementary Material). 
2.3 Biological activity 
The antibiotic activity of 1a and 1b was screened against 
representative bacteria and fungi and the results are shown in 
Table 1, along with data that have been previously reported for 
squalamine.
2
 It is significant that conjugate 1a shows an 
interesting antimicrobial activity against a broad spectrum of 
microorganism, mimicking that reported for squalamine, 
although at a lower level of potency. The inactivity of compound 
1b confirms the observation of Regen
8
 that the polyamine chain 
plays an important role for the biological activity of these 
compounds. This suggests that a strict correlation between 
ionophoric activity in model membranes and antimicrobial 
properties is not possible, probably due to a more favorable 
interaction of the more positively charged 1a with the cell 
membrane.
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Table 1. In vitro antimicrobial activity of peptide conjugates towards fungal or bacterial strains 
 
 Minimum inhibitory concentration (MIC) in µM 
Conjugate C. neoformansa C. albicansa S. aureus 16a,b S. aureus 34a P. aeruginosa 
ATCC 27853 
E. coli ATCC 
25922 
squalamine - 4-8 - 1-2 4-8 1-2 
1a 16 32 32 16 64 32 
1b > 128 > 128 > 128 > 128 > 128 > 128 
a Clinical isolate. b Methicillin-resistant (MRSA) strain. 
 
To study the interaction of the conjugates with the bacterial 
membranes, we performed a permeabilization assay with the E. 
coli ML-35 pYC strain, which constitutively expresses both a 
cytoplasmic β-galactosidase and a periplasmic β-lactamase. A 
damage to the outer membrane allows CENTA, a chromogenic 
substrate for the lactamase, to enter the periplasmic space, where 
its hydrolysis determines an increased absorption at 405 nm. On 
the other hand, a damage to the cytoplasmic membrane allows 2-
nitrophenyl β-D-galactopyranoside (Gal-ONp), a chromogenic 
substrate for the galactosidase, to reach this enzyme, also 
increasing absorption at 405 nm. The results of these tests are 
reported in Figure 4 and clearly show that 1a efficiently 
permeabilizes both the inner and the outer membrane of E. coli 
cells. Interestingly, 1b, even though tested at a higher 
concentration, is poorly active suggesting that the antimicrobial 
activity of 1a is correlated to its ability to permeabilize the 
bacterial membranes. 
  
Figure 4. Permeabilization of the outer (left panel) or inner (right panel) 
membranes of E. coli cells determined by following the hydrolysis of the 
impermeable chromogenic substrates CENTA or Gal-ONp in the presence of 
1a (64 M), 1b (256 M) and without additives (control). 
 
3. Conclusions 
In conclusion, we have reported a new approach to the design 
of synthetic ionophoric molecules using a helical peptide as a 
rigid lipophilic moiety. It was based on an Aib-peptide that 
assumes in membranes a stable 310-helical conformation allowing 
a favorable interaction of the ionophore with the phospholipid 
bilayer. The two conjugates show a high ionophoric activity 
being able to efficiently dissipate a pH gradient and, in the case 
of 1b, to transport Na
+
 across the membrane. Moreover, 1a 
shows a moderate antimicrobial activity against a broad spectrum 
of microorganisms. Although a direct correlation between 
ionophoric activity in model membranes and biological activity is 
complex to demonstrate,
23
 the ability of 1a to permeabilize the 
bacterial membranes suggests that ion transport might play a 
significant role in the mechanism of action of this compound in 
cells. The use of a peptide moiety in the design of acyclic 
ionophores introduces interesting mutation possibilities such as, 
for example, an easy control of its length or the insertion along 
the sequence of functional residues. Studies are in progress to 
evaluate these possibilities and to better define the mechanism of 
action of this new class of biological active synthetic ionophores. 
4. Experimental section 
4.1 General methods 
All commercially available reagents were purchased from 
Aldrich, Fluka and Strem Chemicals and used without 
purification unless otherwise mentioned. Solvents were 
purchased from Aldrich, VWR, Fluka and Riedel, and deuterated 
solvents from Cambridge Isotope Laboratories and Aldrich. 
Reactions were routinely monitored by thin-layer 
chromatography (TLC) on silica gel (precoated F254 Merck 
plates). Chromatography was performed on Merck silica gel 60F-
254 (230÷400 Mesh) and the solvents employed were of 
analytical grade. NMR spectra were recorded on a Jeol 400 
spectrometer (operating at 400 MHz for proton and at 100 MHz 
for carbon) or on Jeol X-270 (operating at 270 MHz for proton 
and at 67.8 MHz for carbon). Chemical shifts (δ) are reported in 
ppm using the solvent residual signal as an internal reference. 
Coupling constants (J) are quoted in Hz. Electrospray mass 
spectra were recorded at 5600 eV with a Perkin Elmer API I 
spectrometer or on a Perspective Biosystems Mariner ESI-TOF 
spectrometer, after dissolving the compounds in CH3OH. Infrared 
spectra (IR) were measured on a Jasco FT/IR-200 instrument. 
Melting points (m.p.) were measured with a Büchi SHP-20 
apparatus and are not corrected. Z-Aib8-OtBu (2),
16,18 
(N
1
,N
4
,N
9
-
tri-tert-butoxycarbonyl)-1,12-diamino-4,9-diazadodecane
24
 (5, 
triboc-spermine), 3,6,9,12,15-pentaoxaheptadecane-1,17-
diamine
25
 (7) 4-[[bis(phenylmethoxy)phosphinyl]oxy]-benzoic 
acid
26
 (10) were synthesized as reported. 
4.2 Synthesis of compounds 1a and 1b. 
N
1
-Z-Aib8-(N
4
,N
9
,N
13
-tri-tert-butoxycarbonyl)-1,12-
diamino-4,9-diazadodecane (3a). 500 mg of Z-Aib8-OtBu 
(MW: 889.09; 0.56 mmol) were dissolved in 10 mL of a 1:1 
CH2Cl2/TFA mixture and stirred at room temperature for 4 h 
monitoring the reaction by TLC (CHCl3/CH3OH, 9/1 v/v). The 
solvent was removed and the residue co-evaporated several times 
with diethyl ether (Et2O), until all the TFA traces have been 
removed, affording Z-(Aib)8-OH (4) in quantitative yield (466 
mg, MW: 832.98; 0.56 mmol), Rf: 0.4 (CHCl3/CH3OH; 9/1). The 
acid thus obtained was suspended in 15 mL of anhydrous CH2Cl2 
and 0.291 g of Py-BOP (MW: 520.39; 0.56 mmol), 0.309 g of 
triboc-spermine (5, MW: 502.69; 0.616 mmol), and 0.18 mL of 
DIEA (MW: 129.24; 1.04 mmol) were added. The reaction 
mixture was stirred at r.t. for 24 hours monitoring the reaction by 
TLC (CHCl3/CH3OH; 95/5). The solvent was then evaporated 
and the residue dissolved in ethyl acetate (EtOAc) (200 mL) and 
washed with KHSO4 5% (2 x 100 mL), H2O (2 x 100 mL) and 
NaHCO3 5% (2 x 100 mL). The organic phase was dried over 
anhydrous Na2SO4, the solvent removed and the crude product 
was purified by column chromatography (silica, toluene/EtOH 
from 95/5 to 91/9) affording 0.422 g of N
1
-Z-Aib8-(N
4
,N
9
,N
13
-tri-
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b) Gal-ONp
tert-butoxycarbonyl)-1,12-diamino-4,9-diazadodecane (3a) 
(MW: 1317.66; 0.32 mmol) as a white solid. Yield = 58 %. Rf: 
0.6 (CHCl3/CH3OH, 9/1); 0.3 (toluene/EtOH, 7/1). 
1
H-NMR 
(CDCl3, 400 MHz):  7.58 (m, 5H, NH); 7.41 (m, 3H, NH); 7.28 
(m, 5H, Ph); 6.55 (s, 1H, NH); 5.95 (s, 1H, NH); 5.02 (s, 2H, 
PhCH2O); 3.07 (m, 12H, CH2 (1, 3, 5, 8, 10, 12)); 1.70 (m, 2H, 
CH2 (2)); 1.40 (m, 81H: 48H CH3 (Aib), 27H tBu, 6H CH2 (6, 7, 
11)). ESI-MS (CH3OH): m/z 1318.7 (M+H
+
), 1340 (M+Na
+
), 
1355.9 (M+K
+
), 678.5 (M+H+K
+
)/2 
N
1
-Z-Aib8-1,17-diamine-3,6,9,12,15-pentaoxaheptadecane 
(8). Z-(Aib)8-OH (4, 0.466 g, MW: 832.98; 0.56 mmol) was 
dissolved in 4 mL of freshly distilled acetic anhydride and 
refluxed for 3 h monitoring the reaction by TLC (CHCl3/CH3OH, 
9/1 v/v). The solvent was removed and the residue co-evaporated 
several times with toluene, until all the Ac2O traces have been 
removed, affording of Z-(Aib)8-Oxl (6) with 97 % yield (0.442 g, 
MW: 814.97; 0.54 mmol), Rf: 0.7 (CHCl3/CH3OH; 9/1). The 
obtained oxazolone (0.256 g, MW: 814.97; 0.31 mmol) was then 
dissolved in 15 mL of dry CH3CN and a solution of 3,6,9,12,15-
pentaoxaheptadecane-1,17-diamine x 2 HCl (7, 0.220 g, MW: 
353.28; 0.62 mmol) and TEA (0.172 mL, MW: 101.19; 1.24 
mmol) in 15 mL of dry CH3CN was added. The reaction mixture 
was kept under stirring at r.t. for 12 h monitoring the reaction by 
TLC (CHCl3/CH3OH; 9/1). The solvent was then removed and 
the crude product was purified by column chromatography 
(silica, CHCl3/CH3OH from 100/0 to 85/15) affording 0.263 g of 
N
1
-Z-Aib8-1,17-diamine-3,6,9,12,15-pentaoxaheptadecane (8) 
(MW: 1095.33; 0.24 mmol). Yield = 77 %. Rf: 0.2 
(CHCl3/CH3OH; 9/1). 
1
H-NMR (CDCl3, 400 MHz):  8.15 (s, 
1H, NH); 7.76 (s, 1H, NH); 7.71 (s, 2H, 2NH); 7.59 (brt, 1H, 
NH); 7.50 (s, 1H, NH); 7.46 (s, 1H, NH); 7.44 (s, 1H, NH); 7.37 
(s, 1H, NH); 7.27 (m, 5H, Ph); 5.10 (s, 2H, PhCH2O); 3.64 (m, 
20H, CH2(2,4,5,7,8,10,11,13,14,16)); 3.51 (m, 2H, CH2(1)); 3.11 
(m, 2H, CH2(17)); 1.50-1.25 (m, 48H, CH3(Aib)). ESI-MS 
(CH3OH): m/z 1096.4 (M+H
+
). 
N
1
-Z-Aib8-(N
17
-tert-butoxycarbonyl)-1,17-diamine-
3,6,9,12,15-pentaoxaheptadecane (3b). The amine 8 (206 mg, 
MW: 1095.33; 0.19 mmol) was dissolved in 10 mL of dry 
CH2Cl2 and 0.264 mL of TEA (MW: 101.19; 0.19 mmol) and 41 
mg of (Boc)2O (MW: 218.25; 0.19 mmol) were added. The 
reaction mixture was stirred at r.t. for 3 hours monitoring the 
reaction by TLC (CHCl3/CH3OH; 9/1). The solvent was then 
evaporated and the residue dissolved in EtOAc (50 mL) and 
washed with KHSO4 5% (2 x 30 mL), H2O (1 x 30 mL) and 
NaHCO3 5% (2 x 30 mL). The organic phase was dried over 
anhydrous Na2SO4, the solvent removed and the crude product 
was purified by column chromatography (silica, CHCl3/CH3OH 
from 100/0 to 90/10) affording 103 mg of N
1
-Z-Aib8-(N
17
-tert-
butoxycarbonyl)-1,17-diamine-3,6,9,12,15-pentaoxaheptadecane 
(3b) (MW: 1195.44; 0.087 mmol). Yield = 45 %. Rf: 0.5 
(CHCl3/CH3OH, 9/1). 
1
H-NMR (CDCl3, 400 MHz):  7.71 (m, 
4H, 4NH); 7.53 (br, 1H, NH); 7.49 (s, 1H, NH); 7.43 (s, 1H, 
NH); 7.32 (m, 6H: 5H Ph, NH); 7.21 (s, 1H, NH); 6.92 (s, 1H, 
NH); 5.08 (s, 2H, PhCH2O); 3.56 (m, 20H, CH2 
(2,4,5,7,8,10,11,13,14,16)); 3.41 (m, 2H, CH2(1)); 3,28 (m, 2H, 
CH2(17)); 1.51-1.23 (m, 57H: 9H, tBu; 48H, CH3 (Aib)). ESI-
MS (CH3OH): m/z 1196 (M+H
+
), 1217.9 (M+Na
+
), 1233.8 
(M+K
+
). 
General procedure for the preparation of the peptide 
conjugates 1. To a solution of 3 (0.087 mmol) in 10 ml of 
CH3OH, 10 mg of 5% Pd/C were added. The flask was evacuated 
and flushed with hydrogen three times. The reaction mixture was 
stirred vigorously, under hydrogen atmosphere, overnight. Then, 
it was filtered through a short pad of Celite
®
 and the solvent 
removed to afford the Z-deprotected 9 with quantitative yield. 9a: 
(MW: 1183.52) Rf: 0.4 (CHCl3/CH3OH; 9/1). 9b: (MW: 1061.31) 
Rf: 0.3 (CHCl3/CH3OH; 9/1). 
14 mg of HOBt (MW: 135.12; 0.104 mmol) and 17 mg of 
EDC (MW: 191.70; 0.087 mmol) were added to a solution of 35 
mg of 10 (MW: 398.35; 0.087 mmol) in 10 mL of dry CH2Cl2 
cooled at 0°C and kept under stirring. After ten minutes, the 
above obtained N-terminus deprotected peptide 9 (0.087 mmol) 
and 0.14 mL of TEA dissolved in 5 mL of anhydrous CH2Cl2 
were added to the reaction mixture. The reaction mixture was 
stirred at r.t. for 24 h monitoring the reaction by TLC 
(CHCl3/CH3OH; 95/5). The solvent was then evaporated and the 
residue dissolved in EtOAc (50 mL) and washed with KHSO4 
5% (2 x 30 mL), H2O (1 x 30 mL) and NaHCO3 5% (2 x 30 mL). 
The organic phase was dried over anhydrous Na2SO4, the solvent 
removed and the crude product was purified by column 
chromatography (silica, CHCl3/CH3OH from 100/0 to 90/10) 
affording the protected peptide conjugates 11. 
N
1
-[4’-[[Bis(phenylmethoxy)phosphinyl]oxy]-benzoyl-Aib8-
(N
4
,N
9
,N
13
-tri-tert-butoxycarbonyl)-1,12-diamino-4,9-
diazadodecane (11a). 68 mg, yield 50 % (MW: 1563.85; 0.044 
mmol). Rf: 0.4 (CHCl3/CH3OH; 95/5). 
1
H-NMR
 
(CDCl3; 400 
MHz):  7.80 (m, 3H: Ar (2
’
,6
’
), NH); 7.69 (m, 4H, NH); 7.47 
(brt, 1H, NH); 7.35 (m, 11H: 10H Bn, 1H, NH); 7.17 (m, 3H: Ar 
(3
’
,5
’
), NH); 7.03 (s, 1H, NH); 6.52 (s, 1H, NH); 5,13 (d, 4H, J = 
9 Hz, PhCH2O); 3.14 ( m, 12H, CH2 (1, 3, 5, 8, 10, 12)); 1.79 (m, 
2H, CH2 (2)), 1.48 (m, 81H: 48H CH3 (Aib), 27H tBu, 6H CH2 
(6, 7, 11)). ESI-MS (CH3OH): m/z 1564.8 (M+H
+
), 1586.7 
(M+Na
+
), 1602.6 (M+K
+
), 793.8 (M+H
+
Na
+
)/2, 801.9 
(M+H+K
+
)/2. 
N
1
-[4’-[[Bis(phenylmethoxy)phosphinyl]oxy]-benzoyl-Aib8-
(N
17
-tert-butoxycarbonyl)-1,17-diamine-3,6,9,12,15-
pentaoxaheptadecane (11b). 41 mg, yield 36 % (MW: 1441.64; 
0.028 mmol). Rf: 0.6 (CHCl3/CH3OH; 9/1). 
1
H-NMR (CDCl3; 
400 MHz):  8.14 (m, 1H, NH); 7.88 (d, 2H, J = 8 Hz, Ar (2
’
,6
’
); 
7.81 (br, 2H, NH); 7.67 (m, 3H, NH); 7.43 (m, 2H, NH); 7.24 (m, 
11H: 10H Bn, 1H NH); 7.14 (d, 2H, J = 8 Hz, Ar (3
’
,5
’
); 7.10 (br, 
1H, NH); 5.04 (d, 4H, J = 8 Hz, PhCH2O); 3.55 (m, 20H, CH2 
(2,4,5,7,8,10,11,13,14,16)); 3.38 (m, 4H, CH2 (1,17)); 1.44 (m, 
57H: 48H, CH3 (Aib), 9H, tBu). ESI-MS (CH3OH): m/z 1441.7 
(M+H
+
), 1463.9 (M+Na
+
), 1479.5 (M+K
+
), 740.9 (M+H+K
+
)/2. 
Full removal of the Boc-protecting groups from the amino 
groups and of the benzyl esters from the phosphate moiety of the 
above obtained peptide conjugates 11 was achieved by dissolving 
the compounds in 3 mL of a 1:1 CH2Cl2/TFA mixture which was 
stirred at room temperature for 12 h, monitoring the reaction by 
TLC (CHCl3/CH3OH, 9/1 v/v). The solvent was removed and the 
residue co-evaporated several times with Et2O, until all the TFA 
traces have been removed, affording peptide conjugates 1 in 
quantitative yield as trifluoroacetate salts. 
N
1
-[4’-[Phosphinyloxy]-benzoyl-Aib8-1,12-diamino-4,9-
diazadodecane (1a) x 3 TFA. 62 mg, (MW: 1425.33; 0.044 
mmol). M.p. = 242 °C. Rf: 0 (CHCl3/CH3OH; 9/1). 
1
H-NMR 
(CD3OD, 400 MHz) :  8.04 (s, 1H, NH); 7.92 (m, 7H, 2H Ar 
(2
’
,6
’
), 5H NH); 7.80 (brt, 1H, NH); 7.70 (bs, 1H, NH); 7.30 (d, 
3H, J = 8 Hz, 2H Ar (3
’
,5
’
), 1H, NH); 3.08 (m, 12H, CH2 (1, 3, 5, 
8, 10, 12)); 2.07 (m, 2H, CH2 (2)); 1.93 (m, 2H, CH2 (11)); 1.81 
(m, 4H, CH2 (6, 7)); 1.48 (m, 48 H, CH3 (Aib)). 
13
C-NMR 
(CD3OD): 178.9, 178.3, 178.2, 177.4, 177.3, 177.2, 177.0, 169.2, 
157.6, 130.3, 130.0, 120.0, 58.2, 58.1, 58.0, 57.9, 57.8, 57.7, 
48.3, 48.2, 46.3, 45.9, 37.8, 37.2, 27.3, 25.5, 25.4, 24.3. HR-ESI-
MS m/z 1083.6621 [M+H
+
] (calcd for C49H88N12O13P 
1083.6331). 
N
1
-[4’-[Phosphinyl]oxy]-benzoyl-Aib8-1,17-diamine-
3,6,9,12,15-pentaoxaheptadecane (1b) x TFA. 36 mg, (MW: 
1275.31; 0.028 mmol). M.p. = 230 °C. Rf: 0 (CHCl3/CH3OH; 
9/1). 
1
H-NMR (CD3OD, 400 MHz):  7.96 (s, 1H, NH); 7.89 (m, 
2H, 2 NH); 7.79 (m, 5H, 2H Ar (2
’
,6
’
), 3H NH); 7.60 (brt, 1H, 
NH); 7.56 (brs, 1H, NH); 7.18 (m, 2H, Ar (3
’
,5
’
)); 6.80 (s, 1H, 
NH); 3.64 (t, 2H, J = 5 Hz, CH2 (2)); 3.53 (m, 18H, CH2 
(4,5,7,8,10,11,13,14,16)); 3.25 (t, 2H, J 5 Hz, CH2(1)); 3.03 (brt, 
2H, CH2 (17)); 1.34 (m, 48H, -CH3 (Aib)). 
13
C-NMR 
(CD3OD/CDCl3 9:1): 178.0, 177.9, 177.7, 177.6, 177.5, 177.2, 
177.0, 176.9, 169.2, 157.6, 130.0, 129.8, 120.9, 71.4, 71.3, 71.2, 
71.1, 71.0, 70.8, 70.7, 70.6, 68.0, 58.3, 58.2, 57.9, 57.8, 57.7, 
57.6, 57.5, 40.6, 40.5, 26.2, 25.9, 25.5, 25.3, 25.2, 25.1. HR-ESI-
MS m/z 1161.5982 [M+H
+
] (calcd for C51H90N10O18P 
1161.6172). 
 
4.3 Ionophoric Activity 
General Procedures. Egg yolk L--phosphatidyl-DL-glycerol 
sodium salt (EYPG, 20 mg/mL chloroform solution) was 
purchased from Avanti Polar Lipids; egg yolk 
phosphatidylcholine (EYPC, 100 mg/mL chloroform solution), 
calcein and 8-hydroxypyrene-1,3,6-trisulfonic acid trisodium salt 
(HPTS) were from Sigma; Triton
®
 X-100 and HEPES buffer 
were from Fluka; all salts were of the best grade available from 
Aldrich and were used without further purification. Size 
exclusion chromatography (SEC) was performed using 
Sephadex
TM
 G-75 or pre-packed columns Sephadex
TM
 G-25 M 
(PD-10) from Amersham Biosciences. Liposome were prepared 
by extrusion using a 10 mL Lipex
TM
 Thermobarrel EXTRUDER 
(Northern Lipids Inc.) connected to a thermostatic bath (25°C). 
The 100 m policarbonate membranes are Nucleopore Track-
Etch Membranes from Whatman. Fluorescence spectra were 
recorded on a Varian Cary Eclipse fluorescence 
spectrophotometer, 
23
Na-NMR-spectra on Jeol GX-270 
spectrometer (270 MHz). All experiments were conducted at 
25°C. The ionophores concentration is given in percent with 
respect to the total concentration of lipid. Stock solutions of 
ionophores were prepared in CH3OH. Control experiments 
showed that the amount of CH3OH added to the vesicular 
suspension in the different experiments (maximum amount 1.6 % 
in volume) did not affect the permeability of the membrane 
23
Na-NMR Transport Assays. A mixture of 150 L of EYPC 
chloroform solution (100 mg/mL, 20 mol), 40 L of EYPG 
chloroform solution (20 mg/mL, 1 mol) and an aliquot of 
CH3OH solution of the desired ionophore was first evaporated 
with Ar-flux to form a thin film and then dried under high 
vacuum for 3h. The lipid film was hydrated in 1 mL of LiCl 
solution (100 mM in H2O/D2O 90:10) for 30 minutes at 40°C. 
The lipid suspension was submitted to 5 freeze-thaw cycles (-
196°C/40°C) using liquid nitrogen and a thermostatic bath, and 
then extruded under nitrogen pressure (15 bar) at room 
temperature (10 extrusions through a 0.1 m polycarbonate 
membrane). 350 L of the lipid dispersion and 350 L of a shift 
reagent solution (4 mM DyCl3·6H2O, 12 mM Na5P3O10, 40 mM 
NaCl in H2O/D2O 90:10) were mixed in a 5 mm NMR-tube. 
During the experiment the spectra were recorded every 30 
minutes over 14 h (accumulation in continuo), the areas of the 
signals were calculated with Jeol Delta software. The % of Na
+
 
inside liposome was calculated respect to the signal of Na
+
 
outside (liposome entrapped volume 2 %). The same experiment 
has been repeated adding an aliquot of CH3OH solution of 
ionophore to the preformed vesicle (single side addition) with 
identical results. 
HPTS assay. A mixture of 150 µL of EYPC chloroform 
solution (100 mg/mL, 20 µmol) and 40 µL of EYPG chloroform 
solution (20 mg/mL, 1 µmol) was first evaporated with Ar-flux to 
form a thin film and then dried under high vacuum for 3 h. The 
lipid cake was hydrated in 1.5 mL of 0.1 mM HPTS solution 
(HEPES 25 mM, 100 mM NaCl, pH 7) for 30 min at 40 °C. The 
lipid suspension was submitted to 5 freeze-thaw cycles (196 
°C/40 °C) using liquid nitrogen and a thermostatic bath, and then 
extruded under nitrogen pressure (15 bar) at room temperature 
(10 extrusions through a 0.1 µm polycarbonate membrane). The 
LUV suspension was separated from extravesicular dye by size 
exclusion chromatography (SEC) (stationary phase: pre-packed 
column Sephadex™ G-25, mobile phase: HEPES buffer) and 
diluted with HEPES buffer to give a stock solution with a lipid 
concentration of 5 mM (assuming 100% of lipids were 
incorporated into liposomes). 104 µL of the lipid suspension 
were placed in a fluorimetric cell, diluted to 3040 µL with the 
same buffer solution used for the liposome preparation and kept 
under gentle stirring. The total lipid concentration in the 
fluorimetric cell was 0.17 mM. An aliquot of solution of the 
ionophore in CH3OH (5-30 µL of the appropriate mother solution 
in order to obtain the desired molcompound/mollipid ratio) was then 
added to the lipid suspension and the cell was incubated at 25 °C 
for 20 min. After incubation the time course of the fluorescence 
emission was recorded for 100 s (λex1 = 460 nm, λex2 = 403 nm, 
λem= 510 nm) and then 50 μL of 0.5 M NaOH were rapidly added 
through an injector port and the fluorescence emission was 
recorded for 400 s. Maximal changes in dye emission were 
obtained by final lysis of the liposomes with detergent (40 μL of 
5% aqueous Triton
®
 X-100). The data set consists of emission 
intensities at 510 nm modulated by alternating excitation at 403 
nm and 460 nm on a 0.5 + 0.5 s cycle. The concentration of the 
conjugate base form of HPTS is related to the emission intensity 
at 510 nm during the period when the dye is excited at 460 nm 
(E460) while the concentration of the protonated form is related to 
the emission intensity at 510 nm during the period when the dye 
is excited at 403 nm (E403). Fluorescence time course were 
normalized using the following equation, where the subscript 0, 
∞ and t denote the emission ratio before the base pulse, after 
detergent lysis, and at an intermediate time, respectively. 
 
 
4.4 Antimicrobial Activity 
The antimicrobial activities of compounds 1a and 1b was 
evaluated by the broth microdilution susceptibility test performed 
according to the guidelines of the Clinical and Laboratory 
Standards Institute (CLSI), to determine the minimum inhibitory 
concentration (MIC) values, as previously described.
27,28
 Two-
fold serial dilutions of each compound were prepared in 96-well 
polypropylene microtiter plates (Sarstedt, Germany) in 5% 
Tryptic Soy Broth (TSB, Difco) in 10 mM Na-phosphate buffer, 
pH 7.4, to a final volume of 50 µl. Each series included a well 
without addition of any compound, as a growth control. A total 
of 50 µl of the adjusted inoculum, diluted in 5% TSB, was then 
added to each well to obtain a final concentration of 
approximately 5x10
5
 cells/ml for bacteria, and 1x10
5
 cells/ml for 
fungi. The microplates were incubated at 37°C for 24h for 
bacteria, or at 30°C for 48h for fungi. The MIC value was taken 
as the lowest concentration of compounds resulting in the 
complete inhibition of visible growth after incubation. Data are 
the mean of at least three independent determinations performed 
in duplicate with values differing by one dilution at the most. 
𝐹𝐼 =
 
𝐸403
𝐸460
 
𝑡
−  
𝐸403
𝐸460
 
0
 
𝐸403
𝐸460
 
∞
−  
𝐸403
𝐸460
 
0
× 100 
  
4.5 Bacterial membrane permeabilization assays 
The permeabilization of the outer membrane of E. coli by the 
compounds was evaluated by following the unmasking of the 
periplasmic hydrolytic enzyme β-lactamase, using extracellular 
CENTA
®
 as substrate,
29
 whilst that of the cytoplasmic membrane 
by unmasking cytoplasmic β-galactosidase activity using 
extracellular 2-nitrophenyl-β-D-galactopyranoside (Gal-ONp) as 
substrate, as described previously.
30,31
 The hydrolysis of both 
chromogenic substrates was monitored at 405 nm on a microplate 
reader. The β-galactosidase constitutive, lactose-permease 
deficient E. coli ML-35 pYC strain was used (~10
7
 cells/ml in 10 
mM phoshate buffer, pH 7.4, containing 100 mM NaCl and 5 
mM glucose), in the presence of 64 µM compound 1a or 256 μM 
compound 1b, and 50 µM CENTA (for the evaluation of the 
outer membrane integrity) or 1.5 mM Gal-ONp (for the 
evaluation of the inner membrane integrity). 
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